[ad_1] New data from the American College of Gastroenterology (ACG) 2020 conference have suggested that vedolizumab is a promising therapeutic agent for long-term maintenance treatment for patients with ulcerative colitis and Crohn’s disease. Previous research, such as the randomized placebo-controlled trials GEMINI, has shown that the humanized, anti-α selective intestinal …
Read More »Vedolizumab shows real-world efficacy against ulcerative colitis, Crohn’s disease
